Merck Responde To The Periodical Of American Medical Articles Of The Association

Merck & Co., Incorporation said today that it is committed to the high standards of the scientific integrity and ethics, and believes that many of the commentaries in a periodical of the American medical notice of the association (JAMA) if liberate and in the introduction related April of the 16 of JAMA1 VIOXX they are false, misleading or context of the lack. The company said that not estve given a chance to answer before the publication. The articles are based on analyses of the originals lead for the consultants used for the experimental lawyers as the part of its work in litigation of the responsibility of VIOXX product, and previously make allegations similar to those advanced for these consultants and lawyers related in the experimentation.

“we are disappointed that such false and deceptive indications on Merck of the experimental lawyers had made its way in a medical periodical,” we said the Dr. Peter S. Kim, president of laboratories of research of Merck. The company said a full evaluation, unbiased of the samples that of the originals of Merck the significant errors in the conclusions had put onward for the authors of JAMA articles. Merck said that it believes that the scientific quarrel and the debate can be obtained when only accurate, the factual information is presented, and that one is the foundation for its interactions with agencies regulatory and the scientific community. “allegation that the deturpados data Merck of mortality of the studies of our Alzheimer are only smooth error,” said the Dr. Kim In the fact, the company said that it supplied given complete of mortality of the studies of the Alzheimer to the administration of the food and the drug of United States, as.well.as the data of mortality of its other studies.

Answering to the affirmations on authorship scientific in the Dr. Kim of JAMA articles it said, “we have explicit politics to govern authorship of the papers related to the medicines and vaccines of Merck, and us we make examination of those very politics seriously. The exterior authors of the papers on the clinical experimentations of Merck referenced in the article of involved JAMA had been intimately in the studies.”

The said company its politics evolved and changeds exceeding a time more specific, as well-taken care of field has the politics of others no do of health, including those of medical periodicals. The politics of the publication of Merck are available in http://www.merck.com.

of “remains committed Merck to bring medicines forward and the vaccines that excepto and improve lives of the person,” said the Dr. Kim. “and we look at onward to continue to connect in quarrels constructive, transparent with wider the scientific and medical community on our innovations.”

For Diante-Olhando the Indication
This release of the press will count “ahead-to look at indications” as that the term is defined in the confidential act of the reform of litigation of seguranas of 1995. These indications are based on current expectations of the management and involve the risks and the uncertainties, that can make with that the results differ materially from those definitive ones in the indications. The indications for ahead-looking at can include the indications regarding the product development, of the potential of the product or the financial performance. No indication for ahead-looking at cannot be guaranteed and the real results can differ materially from those projected ones. Merck does not undertake no obligation to public bring up to date no indication for ahead-looking at, if in consequence of the new information, future events, or in another way. Ahead-to look at indications in this release of the press it must be evaluated together with many uncertainties that affect the business of Merck, particularly those mentioned in the risk factors and indications cautionary in 1A of the article of the form 10-K of Merck per the finished year December 31, 2007, and in all the factors of risk or indications cautionary contained in the periodic reports of the company in the form 10-Q or current reports in the form 8-K, that the company incorporates for the reference.

1 Catherine D. DeAngelis; Phil B. Fontanarosa. Editorial: Impugnating the integrity of medical science: The adverse effect of the influence of the industry. JAMA. 2008;299(15):1833-1835.
Bruce M. Psaty; Richard The Kronmal. Telling findings of mortality in the experimentations of Rofecoxib for the illness of Alzheimer or impairment cognitive: A study of case based on originals of litigation JAMA of Rofecoxib. 2008;299(15):1813-1817.
Joseph S. Ross; Kevin P. Monte; David S. Egilman; Harlan M. Krumholz. Authorship of the guest and to write in related publications the Rofecoxib: A study of case of originals of the industry of litigation of Rofecoxib. JAMA. 2008;299(15):1800-1812.